SCHEDULE: FMR LLC and Abigail P. Johnson Disclose 10.2% Stake in Crescent Biopharma Inc.
Beneficial Ownership Report
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a beneficial ownership of 10.2% of Crescent Biopharma Inc.'s common stock as of June 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 1,414,190 shares of Crescent Biopharma Inc.'s common stock.
- This stake represents 10.2% of the total outstanding common stock of Crescent Biopharma Inc.
- The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- FMR LLC, a Delaware-organized entity, holds sole voting and dispositive power over all 1,414,190 shares.
- Abigail P. Johnson, a U.S. citizen, also reports beneficial ownership of the same 1,414,190 shares, with sole dispositive power but no sole or shared voting power.
- The filing was made under Rule 13d-1(b), indicating that FMR LLC is a parent holding company.
- Fidelity Management & Research Company LLC (an Investment Adviser) and Fidelity Management Trust Company (a Bank) are identified as entities within FMR LLC that beneficially own 5% or more of the shares.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership by a major institutional investor. While the significant stake by FMR LLC and Abigail P. Johnson could be interpreted as a positive signal of institutional confidence, the document itself does not contain operational or financial performance data to assess the company's sentiment beyond this ownership.
Positives
- A significant 10.2% stake by a major institutional investor like FMR LLC, along with its Chairman and CEO Abigail P. Johnson, signals strong institutional interest and potential confidence in Crescent Biopharma Inc.
Industry Context
This filing indicates a significant investment by a major financial institution in a biopharma company, which can be a positive signal within the highly capital-intensive and research-driven biopharma industry. Such investments often reflect confidence in a company's pipeline or market position.
Comparison to Industry Standards
- This document is an ownership disclosure and does not contain performance metrics for comparison. However, a 10.2% stake by a prominent asset manager like FMR LLC is a substantial position, indicating a significant allocation of capital to Crescent Biopharma Inc. This level of institutional ownership is common for publicly traded companies, especially those in growth sectors like biopharma, where large funds often take meaningful positions. No specific comparable companies or projects are mentioned.
Stakeholder Impact
- Shareholders: The disclosure of a significant 10.2% stake by a prominent institutional investor like FMR LLC may be viewed positively by other shareholders, potentially signaling confidence in the company's prospects and attracting further investor interest.
- Management: The presence of a large institutional holder may lead to increased scrutiny or engagement from FMR LLC regarding corporate strategy and performance.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 2025-06-30 | Date of event which requires filing of this statement (ownership position as of this date). |
| 2025-07-07 | Date of filing and signature of the Schedule 13G. |
Keywords
Crescent Biopharma Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biopharma, SEC Filing, Ownership Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.